Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis ; volume:24 ; number:1 ; day:30 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (30.1.2024), 1-11, 12.2024
- Urheber
-
Hildenbrand, Florian F.
Illi, Barbara
von Felten, Stefanie
Bachofner, Jacqueline
Gawinecka, Joanna
Eckardstein, Arnold von
Müllhaupt, Beat
Mertens, Joachim C.
Blümel, Sena
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-023-03116-4
- URN
-
urn:nbn:de:101:1-2024041012401869430625
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hildenbrand, Florian F.
- Illi, Barbara
- von Felten, Stefanie
- Bachofner, Jacqueline
- Gawinecka, Joanna
- Eckardstein, Arnold von
- Müllhaupt, Beat
- Mertens, Joachim C.
- Blümel, Sena
- SpringerLink (Online service)
Ähnliche Objekte (12)
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients
Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients
Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients